WILLIAM MARSH RICE UNIVERSITY

RBL LLC announced the launch of Sentinel BioTherapeutics, a clinical-stage company developing innovative immune-priming therapies for solid tumors that typically respond poorly to checkpoint inhibitors.

Rice University researchers have developed an implantable "cytokine factory" that triggers potent immune responses against metastatic melanoma, pancreatic, and colorectal tumors by locally releasing interleukin-12.

Researchers have developed a novel cancer therapy using near-infrared light to induce molecular vibrations that rupture cancer cell membranes.

Rice University received a $34.9 million grant to develop ROGUE, a bioelectronic implant for type 2 diabetes and obesity treatment, designed to improve patient adherence.

• AstraZeneca and Moffitt Cancer Center are collaborating to accelerate cell therapy development, focusing on CAR T and TCR T therapies for solid tumors. • SWOG Cancer Research Network developed a risk prediction model to identify cancer patients at high risk for emergency room visits during clinical trials. • A national clinical trial is launched by UC San Francisco to repurpose existing drugs for treating traumatic brain injury (TBI), addressing a critical unmet need. • The Ohio State University initiates clinical trials for HOSU-53, a novel DHODH inhibitor, in partnership with Jabez Biosciences, targeting cancer metabolism.

Rice University and Baylor College of Medicine have been awarded $2.8 million by the NHLBI to develop a novel cell therapy for acute respiratory distress syndrome (ARDS).